Business UpdateAug 5, 2026, 07:47 AM
Firefly Neuroscience Evoke™ Assessments Up 291% YoY
AI Summary
Firefly Neuroscience announced a 291% year-over-year increase in Transcranial Magnetic Stimulation (TMS) center customer clinical assessments using its FDA 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™. This significant expansion demonstrates successful execution of the company's growth strategy. Evoke™ helps clinicians identify patterns, differentiate conditions, and tailor TMS treatments more precisely for psychiatric and behavioral health conditions.
Key Highlights
- Transcranial Magnetic Stimulation (TMS) center customer clinical assessments increased by 291% year-over-year.
- This represents a close to four-fold increase in the adoption of Firefly's Evoke™ platform.
- Evoke™ is an FDA 510(k)-cleared, AI-powered EEG/ERP platform.
- The platform helps clinicians identify patterns and differentiate conditions like depression, anxiety, and ADHD.
- Evoke™ enables more precise tailoring and adjustment of TMS treatments.
- Firefly's proprietary database contains over 200,000 EEG/ERP brain scans.
Price Impact
More from AIFF